Berkeley Lights and ChemPartner provide a case study in accelerated discovery of unique Anti-PD-L1 antibodies from spleen versus bone marrow of immunized mice, via single plasma B cell cloning on the Beacon platform.
Learn how antibody discovery is changing in today’s therapeutic space. Case studies presented by Abveris highlight accelerated development of next-generation antibody therapeutics.
Robert Carnahan, PhD, and Seth Zost, PhD, from the Vanderbilt University Medical Center, describe how they have used the Beacon platform, to rapidly discover hundreds of unique antibodies against SARS-CoV-2.
Find out how the Opto Plasma B Discovery workflow simplifies and dramatically reduces the time needed to down-select potential lead candidates, even for difficult membrane proteins.